Monitor upcoming quarterly filings for actual revenue and test volume data to validate the growth trends described in the newsletter.
Drug in focus
BIAF drug pipeline →CyPath Lung
● Neutral Named in this 8-K- Impact
- Phase
- Commercially Available (LDT)
- Time to market
- Already commercially available in the U.S. as a laboratory developed test (LDT) through the company's CLIA-certified lab. CMS reimbursement has been in effect since January 2024.
- Next catalyst
- None dated
What to watchCyPath Lung is already commercial and generating revenue, so the next catalysts are commercial execution metrics (quarterly sales growth, test volumes, physician adoption) and data readouts from the large-scale longitudinal clinical study initiated in March 2026. The stock has fallen ~90% from its 52-week high and recently dipped after Q3 earnings, making sustained sales acceleration the key swing factor for the shares.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 19 $1.85entry
- T+1 · 2d ago −10.81%α −7.17% · $1.65
- T+5 · in 5d Pending
- T+20 · in 26d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
bioAffinity Technologies released a newsletter highlighting record CyPath Lung test volume in October 2026, a 109% increase in test unit sales year-to-date, and a new federal healthcare distribution agreement with AvMEDICAL. The filing is a routine business update with no material financial data or guidance.
Key Facts
- Record CyPath Lung testing volume in October 2026
- CyPath Lung test unit sales in Q3 doubled year to date over 2025
- 109% increase in test unit sales, 89% increase in ordering physicians, 48% growth in orders from existing physicians
- Nationwide federal healthcare distribution agreement with AvMEDICAL
- 14 issued and 24 pending diagnostic patents; new patent protection in Hong Kong, China and Japan
- Announced $4 million raised in a registered direct financing on October 9, 2026
- Company market cap is $4M
Financial Impact
No financial figures reported in this filing; prior $4M financing noted in newsletter
Risk Factors
- Forward-looking statements about commercial momentum and physician adoption may not materialize
- Company has a $4M market cap and may require additional financing to fund operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-053172 |
| Exhibit: ex99-1.htm | 0001493152-26-053172 |
| Document: 0001493152-26-053172-index-headers.html | 0001493152-26-053172 |
| Document: 0001493152-26-053172-index.html | 0001493152-26-053172 |
| Document: 0001493152-26-053172.txt | 0001493152-26-053172 |
Track record
37 reports on BIAF
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +66.50% at T+60 after the Jul 31, 2026 report. 12 of 16 went positive at some point.
Filters
- Nov 19, 20262d ago SC 13G Neutral 4/10 Entry $2.01 Now $1.65 −17.91% settles Feb 19
- Nov 19, 20262d ago Insider Buy Bullish 5/10 Entry $2.01 Now $1.65 −17.91% settles Feb 19
- Nov 19, 20262d ago 3 Neutral 3/10 Entry $1.85 Now $1.65 −10.81% settles Feb 18
- Nov 19, 20262d ago 8-K Neutral 2/10 Viewing Entry $1.85 Now $1.65 −10.81% settles Feb 18
- Nov 17, 20264d ago 8-K Neutral 3/10 Entry $1.93 Now $1.65 −14.51% settles Feb 16
- Nov 6, 202615d ago 8-K Bearish 5/10 Entry $2.26 Now $1.65 +26.99% settles Feb 5
- Nov 3, 202618d ago 424B5 Bearish 6/10 Entry $2.93 Now $1.65 +43.69% settles Feb 2
- Nov 2, 202619d ago 424B5 Bearish 5/10 Entry $3.19 Now $1.65 +48.28% settles Feb 1
- Oct 29, 202623d ago 8-K Neutral 2/10 Entry $3.03 Now $1.65 −45.54% settles Jan 27
- Oct 23, 202629d ago DEF 14A Neutral 5/10 Entry $2.83 Now $1.65 −41.70% settles Jan 22
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers